Drug Profile
Research programme: anticancer potentiating agents - Oncore Therapeutics
Alternative Names: Anticancer potentiating agents research programme; Potentiating agents - Oncore Therapeutics; PTA projectLatest Information Update: 06 Aug 2009
Price :
$50
*
At a glance
- Originator Pfizer
- Class Carbamates; Steroids
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 27 May 2005 Preclinical trials in Cancer in Switzerland (Parenteral)
- 27 May 2005 Preclinical trials in Cancer in Switzerland (PO)